Proportions of participants responding to treatment ≥ 50% reduction in depression score from baseline to end of treatment. A larger RR indicates greater response to treatment in the SAMe group · treatment‐resistant depression in adults
Augmentation of current antidepressant (fluoxetine 20 mg/d) with… may leads to higher response (≥ 50% reduction in HAM‐D score) compared with augmentation of current antidepressant (fluoxetine 20 mg/d) with… (low certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (fluoxetine 20 mg/d) with… may leads to higher remission (HAM‐D total score ≤ 7) compared with augmentation of current antidepressant (fluoxetine 20 mg/d) with… (low certainty).
1 finding from 1 review
Intervention not reported
Physical well‐being SF‐36 Physical Component Summary Score 0 to 100, higher scores indicate higher levels of physical well‐being Immediately post‐intervention · Cancer patients with cognitive impairment due to systemic cancer treatment
1 finding from 1 review
Intervention not reported
Physical well‐being SF‐36 Physical Component Summary Score 0‐100, higher scores indicate higher levels of physical well‐being Two‐months post‐intervention · Cancer patients with cognitive impairment due to systemic cancer treatment
1 finding from 1 review
Intervention not reported
Psychological well‐being SF‐36 Mental Component Summary Score 0 to 100, higher scores indicate higher levels of physical well‐being Immediately post‐intervention · Cancer patients with cognitive impairment due to systemic cancer treatment
1 finding from 1 review
Intervention not reported
Psychological well‐being SF‐36 Mental Component Summary Score 0 to 100, higher scores indicate higher levels of physical well‐being Two‐months post‐intervention · Cancer patients with cognitive impairment due to systemic cancer treatment
1 finding from 1 review
Dropout · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in dropout ‐ All studies objective compared with placebo according to any definition (low certainty).
1 finding from 1 review
Adverse events ‐ Withdrawn for medical reasons · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants probably leads to higher adverse events ‐ Withdrawn for medical reasons compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Drupout ‐ Tricyclics versus placebo · patients with depression during opioid agonist treatment for opioid dependence
The intervention showed no clear difference in drupout ‐ Tricyclics versus placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Drupout ‐ SSRI versus placebo · patients with depression during opioid agonist treatment for opioid dependence
The intervention showed no clear difference in drupout ‐ SSRI versus placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Severity of depression dichotomous measures ‐ Tricyclics versus placebo: "very much" or "much" improvement on the Clinical Global Impression scale · patients with depression during opioid agonist treatment for opioid dependence
The intervention probably leads to higher severity of depression dichotomous measures ‐ Tricyclics versus… (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Withdrawn for medical reasons: Tricyclics versus placebo · patients with depression during opioid agonist treatment for opioid dependence
The intervention leads to higher adverse events ‐ Withdrawn for medical reasons: Tricyclics versus… (high certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Withdrawn for medical reasons: SSRI versus placebo · patients with depression during opioid agonist treatment for opioid dependence
The intervention showed no clear difference in adverse events ‐ Withdrawn for medical reasons: SSRI versus placebo (high certainty).
1 finding from 1 review
Dropout ‐ Studies with low risk of bias · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in dropout ‐ Studies with low risk of bias compared with placebo according to any definition (high certainty).
1 finding from 1 review
> 50% reduction in depressive symptoms · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in severity of depression dichotomous measures ‐ >50% reduction in… compared with placebo according to any definition (low certainty).
1 finding from 1 review
Severity of depression dichotomous measures ‐ "very much" or "much" improved on the Clinical Global Impression Scale · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants may leads to higher severity of depression dichotomous measures ‐ "very much" or "much"… compared with placebo according to any definition (low certainty).
1 finding from 1 review
Adverse events ‐ Withdrawn for medical reasons · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants probably leads to higher adverse events ‐ Withdrawn for medical reasons compared with placebo according to any definition (moderate certainty).
1 finding from 1 review
Dropout · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in dropout compared with placebo (moderate certainty).
1 finding from 1 review
Severity of depression dichotomous measures ‐ "very much" or "much" improved on the Clinical Global Impression Scale · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants may leads to higher severity of depression dichotomous measures ‐ "very much" or "much"… compared with placebo (low certainty).
1 finding from 1 review
> 50% reduction in depressive symptoms · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in severity of depression dichotomous measures ‐ >50% reduction in… compared with placebo (low certainty).
1 finding from 1 review